Welcome to our dedicated page for Insmed SEC filings (Ticker: INSM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Insmed鈥檚 filings can feel like decoding a clinical study: dozens of pages on nebulizer technology, R&D burn, and FDA timelines hidden in dense legal text. If you have ever wondered, 鈥淲here can I find Insmed鈥檚 quarterly earnings report 10-Q filing?鈥� or needed real-time alerts on Insmed insider trading Form 4 transactions before the market reacts, you are not alone.
Stock Titan removes that friction. Our AI engine highlights trial-related milestones, breaks down cash runway assumptions, and tags every risk factor so you can understand Insmed SEC documents with AI in minutes, not hours. From the Insmed annual report 10-K simplified to each 8-K material events explained, we stream filings from EDGAR the moment they post and layer in plain-English summaries, key metrics, and historical comparisons.
Use cases include:
- Instant email or SMS alerts on Insmed Form 4 insider transactions real-time to monitor executive stock moves.
- Side-by-side Insmed earnings report filing analysis to track R&D expense versus pipeline progress across quarters.
- Quick look-ups of the latest Insmed proxy statement executive compensation without paging through appendices.
Every filing type is covered鈥�10-K, 10-Q, 8-K, S-3, DEF 14A鈥攃omplete with AI-powered summaries, red-flag detection, and searchable text. Whether you are modeling milestone payments or gauging launch readiness for ARIKAYCE, our platform surfaces the insights hidden in technical jargon. Save hours, spot trends early, and make confident decisions with comprehensive coverage of Insmed SEC filings explained simply.
Form 144 filed for Insmed, Inc. (INSM) reports a proposed sale of 10,000 shares of common stock through Merrill Lynch in Orlando, to be executed on or about 08/12/2025 on NASDAQ with an aggregate market value of $1,215,350. The filing lists total shares outstanding of 211,374,786, which makes the proposed block a very small fraction of the company's capitalization.
The securities to be sold were acquired via stock option transactions reported on 05/18/2018 (6,702 shares) and 05/16/2019 (6,066 shares). Several identifying fields in the filing appear blank or unspecified, and the form includes the standard representation that the seller does not possess undisclosed material adverse information.
Insmed announced FDA approval of BRINSUPRI (brensocatib) 10 mg and 25 mg tablets, an oral once-daily treatment for non-cystic fibrosis bronchiectasis in adults and children 12 years and older. The company attached a press release and an approval presentation as Exhibits 99.1 and 99.2 and will host a conference call with a live webcast to discuss the approval. The filing notes the Item 7.01 materials are not deemed "filed" for purposes of Section 18. The report does not include financial results, revenue guidance, launch timing, or other commercial details.
Insmed (INSM) Q2 2025 10-Q highlights
- Net sales up 19% to $107.4 m; six-month sales rose 21% to $200.2 m, driven by ARIKAYCE growth in Japan (+45%) and continued U.S. demand.
- Spending accelerated. R&D jumped 21% YoY to $177.2 m and SG&A 45% to $154.8 m. Total operating expenses were $420.3 m, lifting the operating loss to $312.9 m (-8% YoY).
- Wider bottom-line loss. Net loss reached $321.7 m (-$1.70/sh) versus $300.6 m (-$1.94/sh) a year ago; six-month loss deepened to $578.3 m.
- Balance-sheet reset. All $575 m 0.75% 2028 converts were converted/redemed in Q2, cutting long-term debt nearly 51% to $538.5 m (term loans only) and adding 17.9 m shares. Shareholders鈥� equity rose to $1.25 b from $0.29 b.
- Liquidity bolstered. Cash & cash equivalents soared to $1.28 b (vs. $0.56 b YE-24) after $823.5 m equity raise and $146 m draw of Tranche B term loan; total liquidity (cash+securities) $1.86 b.
- Cash burn rising. Operating cash outflow was -$468 m for H1 vs. -$307 m prior-year.
- Contingent consideration liability climbed to $246 m (+46% YTD) on Motus/AlgaeneX milestones.
Company says cash on hand funds operations for 鈮�12 months while it advances brensocatib Phase 3, TPIP, INS1201 and expands ARIKAYCE indications. No forward guidance provided.
FAQ
What is the current stock price of Insmed (INSM)?
What is the market cap of Insmed (INSM)?
